一例罕见的分泌醛固酮的肾上腺皮质癌的全外显子测序

基础医学与临床 ›› 2020, Vol. 40 ›› Issue (9): 1190-1194.

一例罕见的分泌醛固酮的肾上腺皮质癌的全外显子测序

王慧萍^1,2, 常晓燕³, 马晓森¹, 童安莉^1*

1.中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室, 北京 100730;
2.河北北方学院研究生学院, 河北张家口 075000;
3.中国医学科学院北京协和医学院北京协和医院病理科, 北京 100730

收稿日期:2020-03-21 修回日期:2020-05-25 出版日期:2020-09-05 发布日期:2020-09-04
通讯作者: ^*tonganli@hotmail.com
基金资助:
国家自然科学基金(81770427)

Whole-exome sequencing for a rare case of aldosterone-producing adrenocortical carcinoma

WANG Hui-ping^1,2, CHANG Xiao-yan³, MA Xiao-sen¹, TONG An-li^1*

1. Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission;
2. Graduate school, Hebei North University, Zhangjiakou 075000, China;
3. Department of pathology,Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730

Received:2020-03-21 Revised:2020-05-25 Online:2020-09-05 Published:2020-09-04
Contact: ^*tonganli@hotmail.com

摘要/Abstract

摘要： 目的拟对一例分泌醛固酮的肾上腺皮质癌(ACC)进行全外显子测序分析,筛选与分泌醛固酮的ACC发生发展相关的突变基因。方法选取分泌醛固酮的ACC患者一例;收集患者的临床资料;并取患者的肿瘤组织的石蜡切片及患者的外周血,提取DNA,进行全外显子测序;分析患者的胚系突变和肿瘤组织中的体系突变。结果在患者外周血DNA中未发现已报道的与遗传性肾上腺皮质肿瘤及家族性醛固酮增多症相关的致病基因变异。在肿瘤组织中共发现349个体系基因突变,突变基因主要富集在肿瘤发生和钙信号等通路上。CTNNB1、CDKN2A和MSH6等与肾上腺肿瘤生长相关的基因发生了突变,但未发现与醛固酮合成有关的KCNJ5、ATP1A1、ATP2B3和CACNA1D等基因突变。结论该例分泌醛固酮的ACC的肿瘤发生与CTNNB1、CDKN2A和MSH6等基因突变有关,但其醛固酮合成增加的机制仍不明确。

关键词: 分泌醛固酮的肾上腺皮质癌, 体系突变, 全外显子测序

Abstract: Objective Aldosterone-producing adrenocortical carcinoma(ACC) is an uncommon disease.In this paper, the genetic mutations of aldosterone-producing ACC are studied by whole-exome sequencing. Methods Clinical data of the patient with aldosterone-producing ACC were collected. DNA was extracted from paraffin-embedded tissues and peripheral blood, then the whole-exome sequencing was carried out to identify germline and somatic mutations. Results There was no mutation associated with hereditary adrenocortical tumors and familial hyperaldosteronism in peripheral blood DNA. A total of 349 somatic mutations were found in tumor tissues, which were mainly enriched in tumorigenesis and calcium signaling pathways. Mutations related to the growth of adrenocortical tumor, CTNNB1, CDKN2A and MSH6, were detected, while no mutation related to aldosterone synthesis as KCNJ5, ATP1A1, ATP2B3 and CACNA1D was found in the tumor tissue. Conclusions The tumor- igenesis of aldosterone-producing ACC is related to CTNNB1, CDKN2A and MSH6, but the mechanism of promoting aldosterone production is still uncertain.

Key words: aldosterone-producing adrenocortical carcinomas, somatic mutation, whole-exome sequencing

中图分类号:

320.2440

王慧萍, 常晓燕, 马晓森, 童安莉. 一例罕见的分泌醛固酮的肾上腺皮质癌的全外显子测序[J]. 基础医学与临床, 2020, 40(9): 1190-1194.

WANG Hui-ping, CHANG Xiao-yan, MA Xiao-sen, TONG An-li. Whole-exome sequencing for a rare case of aldosterone-producing adrenocortical carcinoma[J]. Basic & Clinical Medicine, 2020, 40(9): 1190-1194.

参考文献

[1] Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives[J]. J Intern Med, 2019, 285: 126-148.
[2] Funder JW, Carey RM, Mantero F, et al. The manage-ment of primary aldosteronism: Case detection, diagnosis, and treatment: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2016, 101: 1889-1916.
[3] Griffin AC, Kelz R, Livolsi VA. Aldosterone-secreting adrenal cortical carcinoma. A case report and review of the literature[J]. Endocr Pathol, 2014, 25: 344-349.
[4] Song MS, Seo SW, Bae SB, et al. Aldosterone-producing adrenocortical carcinoma without hypertension[J]. Korean J Intern Med, 2012, 27: 221-223.
[5] Monticone S, Buffolo F, Tetti M, et al. Genetics in endocrinology: the expanding genetic horizon of primary aldosteronism[J]. Eur J Endocrinol, 2018, 178: R101-R111.
[6] Tadjine M, Lampron A, Ouadi L, et al. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas[J]. Clin Endocrinol (Oxf), 2008, 68: 264-270.
[7] Gao C, Wang Y, Broaddus R, et al. Exon 3 mutations of CTNNB1 drive tumorigenesis: A review[J]. Oncotarget, 2018, 9: 5492-5508.
[8] Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma[J]. Cancer Cell, 2016, 29: 723-736.
[9] Mouat IC, Omata K, Mcdaniel AS, et al. Somatic mutations in adrenocortical carcinoma with primary aldoster-onism or hyperreninemic hyperaldosteronism[J]. Endocr Relat Cancer, 2019, 26: 217-225.
[10] Cheng HH, Sokolova AO, Schaeffer EM, et al. Germline and somatic mutations in prostate cancer for the clinician[J]. J Natl Compr Canc Netw, 2019, 17: 515-521.
[11] Tamura K, Kaneda M, Futagawa M, et al. Genetic and genomic basis of the mismatch repair system involved in lynch syndrome[J]. Int J Clin Oncol, 2019, 24: 999-1011.
[12] Lynch HT, Snyder CL, Shaw TG, et al. Milestones of lynch syndrome: 1895-2015[J]. Nat Rev Cancer, 2015, 15: 181-194.
[13] Karamurzin Y, Zeng Z, Stadler ZK, et al. Unusual DNA mismatch repair-deficient tumors in lynch syndrome: A report of new cases and review of the literature[J]. Hum Pathol, 2012, 43: 1677-1687.
[14] Kaur RJ, Pichurin PN, Hines JM, et al. Adrenal cortical carcinoma associated with lynch syndrome: A case report and review of literature[J]. J Endocr Soc, 2019, 3: 784-790.